Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | CHRNB4 | P30926 | 4/20 | 0.33 |
| ▸ | CHRNA3 | P32297 | 4/20 | 0.33 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.33 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.33 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3587072 | 0.88 | GAA (0.37) | GAAKDM4EMAPTCHRNB4CHRNA3 | |
| SCHEMBL3591700 | 0.88 | GAA (0.37) | GAAKDM4EMAPTCHRNB4CHRNA3 | |
| SCHEMBL13544000 | 0.88 | GAA (0.37) | GAAKDM4EMAPTCHRNB4CHRNA3 | |
| SCHEMBL3587070 | 0.88 | GAA (0.37) | GAAKDM4EMAPTCHRNB4CHRNA3 | |
| SCHEMBL11559294 | 0.86 | GAA (0.38) | GAAKDM4EMAPTCHRNB4CHRNA3 | |
| SCHEMBL27663129 | 0.81 | CHEK1 (0.42) | GAAMAPT | |
| SCHEMBL27663070 | 0.81 | GAA (0.45) | GAAMAPTCREBBP | |
| SCHEMBL16193913 | 0.78 | CYP19A1 (0.39) | GAAMAPTNPC1LMNARAB9A | |
| SCHEMBL5466546 | 0.77 | GAA (0.57) | GAAMAPTCREBBPLMNASMN1; SMN2 | |
| SCHEMBL11560241 | 0.76 | NQO2 (0.33) | GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9101634-B2 | Application of 2, 3-dihydro-3-hydroxymethyl-6-amino-[1,4]-benzoxazine in preparation of drugs inducing embryonic stem cells to differentiate to vascular endothelial cells | SHANDONG UNIVERSITY (CN) | 2015-08-11 | — | — | US | claimed |
| US-20120123116-A1 | APPLICATION OF 2, 3 - DIHYDRO-3 - HYDROXYMETHYL -6 - AMINO - [1,4 ] - BENZOXAZINE IN PREPARATION OF DRUGS INDUCING EMBRYONIC STEM CELLS TO DIFFERENTIATE TO VASCULAR ENDOTHELIAL CELLS | SHANDONG UNIVERSITY (CN) | 2012-05-17 | — | — | US | claimed |
| EP-2638014-B1 | N-SULFONYLATED TETRAHYDROQUINOLINES AND RELATED BICYCLIC COMPOUNDS FOR INHIBITION OF ROR-GAMMA ACTIVITY AND THE TREATMENT OF DISEASES | LYCERA CORP (US) | 2017-01-04 | — | — | EP | disclosed |
| US-9101634-B2 | Application of 2, 3-dihydro-3-hydroxymethyl-6-amino-[1,4]-benzoxazine in preparation of drugs inducing embryonic stem cells to differentiate to vascular endothelial cells | SHANDONG UNIVERSITY (CN) | 2015-08-11 | — | — | US | disclosed |
| US-9101634-B2 | Application of 2, 3-dihydro-3-hydroxymethyl-6-amino-[1,4]-benzoxazine in preparation of drugs inducing embryonic stem cells to differentiate to vascular endothelial cells | SHANDONG UNIVERSITY (CN) | 2015-08-11 | — | — | US | disclosed |
| US-9101634-B2 | Application of 2, 3-dihydro-3-hydroxymethyl-6-amino-[1,4]-benzoxazine in preparation of drugs inducing embryonic stem cells to differentiate to vascular endothelial cells | SHANDONG UNIVERSITY (CN) | 2015-08-11 | — | — | US | disclosed |
| US-9101634-B2 | Application of 2, 3-dihydro-3-hydroxymethyl-6-amino-[1,4]-benzoxazine in preparation of drugs inducing embryonic stem cells to differentiate to vascular endothelial cells | SHANDONG UNIVERSITY (CN) | 2015-08-11 | — | — | US | disclosed |
| US-9101634-B2 | Application of 2, 3-dihydro-3-hydroxymethyl-6-amino-[1,4]-benzoxazine in preparation of drugs inducing embryonic stem cells to differentiate to vascular endothelial cells | SHANDONG UNIVERSITY (CN) | 2015-08-11 | — | — | US | disclosed |
| CN-102784148-A | Application of 2,3-dihydro-3-methylol-6-amino-(1,4)-benzoxazine to preparation of medicine for stabilizing atherosclerosis plaques | UNIV SHANDONG | 2012-11-21 | — | — | CN | disclosed |
| CN-102784148-A | Application of 2,3-dihydro-3-methylol-6-amino-(1,4)-benzoxazine to preparation of medicine for stabilizing atherosclerosis plaques | UNIV SHANDONG | 2012-11-21 | — | — | CN | disclosed |
| US-20120123116-A1 | APPLICATION OF 2, 3 - DIHYDRO-3 - HYDROXYMETHYL -6 - AMINO - [1,4 ] - BENZOXAZINE IN PREPARATION OF DRUGS INDUCING EMBRYONIC STEM CELLS TO DIFFERENTIATE TO VASCULAR ENDOTHELIAL CELLS | SHANDONG UNIVERSITY (CN) | 2012-05-17 | — | — | US | disclosed |
| US-20120123116-A1 | APPLICATION OF 2, 3 - DIHYDRO-3 - HYDROXYMETHYL -6 - AMINO - [1,4 ] - BENZOXAZINE IN PREPARATION OF DRUGS INDUCING EMBRYONIC STEM CELLS TO DIFFERENTIATE TO VASCULAR ENDOTHELIAL CELLS | SHANDONG UNIVERSITY (CN) | 2012-05-17 | — | — | US | disclosed |
| US-20120123116-A1 | APPLICATION OF 2, 3 - DIHYDRO-3 - HYDROXYMETHYL -6 - AMINO - [1,4 ] - BENZOXAZINE IN PREPARATION OF DRUGS INDUCING EMBRYONIC STEM CELLS TO DIFFERENTIATE TO VASCULAR ENDOTHELIAL CELLS | SHANDONG UNIVERSITY (CN) | 2012-05-17 | — | — | US | disclosed |
| US-20120123116-A1 | APPLICATION OF 2, 3 - DIHYDRO-3 - HYDROXYMETHYL -6 - AMINO - [1,4 ] - BENZOXAZINE IN PREPARATION OF DRUGS INDUCING EMBRYONIC STEM CELLS TO DIFFERENTIATE TO VASCULAR ENDOTHELIAL CELLS | SHANDONG UNIVERSITY (CN) | 2012-05-17 | — | — | US | disclosed |
| WO-2011143927-A1 | USE OF 2,3-DIHYDRO-3-HYDROXYMETHYL-6-AMINO-1,4-BENZOXAZINE IN PREPARING MEDICAMENTS FOR INDUCING EMBRYONIC STEM CELLS TO DIFFERENTIATE INTO VASCULAR ENDOTHELIAL CELLS | 山东大学 (CN) | 2011-11-24 | — | — | WO | disclosed |
| CN-1847232-A | 2,3-dihydro-3-hydroxymethyl-[1,4]-benzoxazine derivative and its prepn process | UNIV SHANDONG (CN) | 2006-10-18 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120123116-A1 | APPLICATION OF 2, 3 - DIHYDRO-3 - HYDROXYMETHYL -6 - AMINO - [1,4 ] - BENZOXAZINE IN PREPARATION OF DRUGS INDUCING EMBRYONIC STEM CELLS TO DIFFERENTIATE TO VASCULAR ENDOTHELIAL CELLS | EDF1, CBX6, MCL1 | GAA 4233/4885KDM4E 159/4885MAPT 4645/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.